Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Guidance on Optimizing Treatment Strategies for Acute Lymphoblastic Leukemia
  • CME
  • CE

Amir Fathi, MD
Released: April 16, 2020

Immunotherapies in B-Cell ALL

B-Cell ALL: New Treatment Directions

Next, we will discuss several immunotherapies for the treatment of B-cell ALL that represent a new era of therapeutics. These include ADCs such as InO, the BiTE blinatumomab, and CAR T‑cell therapies.

Current Immunotherapy Targets in Adult Relapsed/Refractory ALL

InO, an ADC construct, binds to CD22 on the surface of B‑cell lymphoblasts followed by internalization and release of a toxic agent that kills the target tumor cells. Blinatumomab, a BiTE construct, can bind both CD19 on the surface of B‑cell lymphoblasts and CD3 on the surface of T-cells, bringing leukemia cells into proximity with the activated T-cells and causing immunologically mediated cytotoxicity. CAR T-cell therapy consists of genetically modified CD19‑targeted T‑cells that attack CD19‑expressing malignant lymphoid blasts.

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
Jazz Pharmaceuticals, Inc.
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?